STERIS plc (NYSE:STE) Shares Acquired by Aureus Asset Management LLC

Aureus Asset Management LLC raised its stake in shares of STERIS plc (NYSE:STE) by 0.4% in the 3rd quarter, Holdings Channel reports. The fund owned 30,516 shares of the medical equipment provider’s stock after acquiring an additional 116 shares during the quarter. Aureus Asset Management LLC’s holdings in STERIS were worth $7,401,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Massachusetts Financial Services Co. MA raised its stake in STERIS by 13.7% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 6,442,805 shares of the medical equipment provider’s stock valued at $1,414,453,000 after acquiring an additional 778,613 shares during the last quarter. Impax Asset Management Group plc raised its stake in STERIS by 29.7% during the 2nd quarter. Impax Asset Management Group plc now owns 1,150,517 shares of the medical equipment provider’s stock valued at $251,663,000 after acquiring an additional 263,383 shares during the last quarter. Principal Financial Group Inc. raised its stake in STERIS by 9.5% during the 3rd quarter. Principal Financial Group Inc. now owns 1,114,224 shares of the medical equipment provider’s stock valued at $270,230,000 after acquiring an additional 96,336 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in STERIS by 12.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 840,194 shares of the medical equipment provider’s stock valued at $184,439,000 after acquiring an additional 95,412 shares during the last quarter. Finally, Raymond James & Associates increased its position in STERIS by 1.5% during the 3rd quarter. Raymond James & Associates now owns 801,144 shares of the medical equipment provider’s stock worth $194,309,000 after purchasing an additional 12,005 shares during the period. 94.69% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at STERIS

In other STERIS news, SVP Cary L. Majors sold 1,682 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $217.32, for a total transaction of $365,532.24. Following the transaction, the senior vice president now owns 11,372 shares of the company’s stock, valued at $2,471,363.04. This represents a 12.88 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Michael J. Tokich sold 23,332 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the transaction, the chief financial officer now directly owns 42,930 shares in the company, valued at approximately $10,603,710. This represents a 35.21 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Piper Sandler upgraded STERIS from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $230.00 to $260.00 in a research report on Thursday, October 24th. JMP Securities reiterated a “market outperform” rating and set a $265.00 target price on shares of STERIS in a research report on Monday, November 18th. StockNews.com cut STERIS from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 29th. Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a research report on Friday, November 8th. Finally, KeyCorp boosted their target price on STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 3rd. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.00.

STERIS Stock Performance

STE opened at $219.06 on Monday. The stock has a market cap of $21.62 billion, a P/E ratio of 50.01 and a beta of 0.85. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.41 and a quick ratio of 1.55. The stock’s 50 day simple moving average is $225.01 and its 200 day simple moving average is $228.23. STERIS plc has a 1-year low of $195.47 and a 1-year high of $248.24.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, topping analysts’ consensus estimates of $2.12 by $0.02. The business had revenue of $1.33 billion for the quarter, compared to analysts’ expectations of $1.33 billion. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The company’s revenue was up 7.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.03 EPS. As a group, equities analysts anticipate that STERIS plc will post 9.15 EPS for the current fiscal year.

STERIS Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 1.04%. The ex-dividend date is Tuesday, November 19th. STERIS’s dividend payout ratio (DPR) is presently 52.05%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.